肾康注射液联合海昆肾喜胶囊治疗慢性肾衰竭临床研究
Clinical Observation of Shenkang Injection Combined with Haikunshenxi Capsule in the Treatment of Chronic Renal Failure(CRF)
丁志勇 1赵艳 1盛清华1
作者信息
- 1. 276800 山东省日照市东港区人民医院肾内科
- 折叠
摘要
目的观察肾康注射液联合海昆肾喜胶囊胶囊治疗慢性肾衰竭的疗效.方法68例患者随机分成治疗组(36例)和对照组(32例)，在常规治疗的基础上，治疗组给予肾康注射液联合海昆肾喜胶囊治疗，对照组予灯盏花素注射液，观察治疗前后疗效，血尿素氮(BUN)、血肌酐(Scr)、血β2微球蛋白(β2-M)、血清胱抑素 C(CysC)水平变化.结果治疗组明显优于对照组，临床总有效率88.9%.BUN、Scr、β2-M、CysC 下降明显(P <0.05).2组均未见严重不良反应发生.结论肾康注射液联合海昆肾喜胶囊治疗慢性肾衰竭疗效确切，不良反应少，可改善临床症状，保护肾功能，延缓肾衰的进展.
Abstract
Objective To observe the therapeutic efficacy of Shenkang injection combined with Haikunshenxi capsule in treatment of patients with chronic renal failure. Methods 68 patients with chronic renal failure were randomly divided into treatment group(36 cases) and control group(32 cases). Shenkang injection combined with Haikunshenxi capsule were given based on the routine treatment in treatment group, while Brevis capus Injection was performed in control group. Blood urea nitrogen(BUN), serum creatinine(Scr), β2-microglobulin(β2-M), and cystatinC(CysC) of patients in each group were observed pre and post treatment. Results The therapeutic efficacy of treatment group(effective rate 88.9% ) was better than that of control group(effective rate 68.8%). The decreases of blood urea nitrogen(BUN), serum creatinine(Scr), β2-microglobulin(β2-M), and cystatinC(CysC) in treatment group were significantly more than those in control group(P <0.05). There were no serious ADRs found in two groups. Conclusions Shenkang injection combined with Haikunshenxi capsule not only relieve the clinical symptom of the patients with chronic renal failure, but also improve their renal function with no obvious side-effect and postpone the deterioration of the patients with chronic renal failure.
关键词
肾康注射液/海昆肾喜胶囊/慢性肾衰竭/血清胱抑素CKey words
Shenkang injection/Haikunshenxi capsule/Chronic renal failure/CystatinC引用本文复制引用
出版年
2013
NETL
NSTL
维普
万方数据